Kiyoshi Sugihara
- Oncology top 10%
- Radiology, Nuclear Medicine and Imaging top 10%
- Pulmonary and Respiratory Medicine
- Molecular Biology
- Cancer Research
- Co-authors
- Toshinori AgatsumaTakahiro JikohTakashi NakadaYuki AbeTeiji WadaTetsufumi KogaMasayo KakutaMikiko Suzuki
- Topics
- Antibiotics Pharmacokinetics and Efficacy (4 papers)Antibiotic Resistance in Bacteria (3 papers)HER2/EGFR in Cancer Research (2 papers)
- Partner nations
- JapanGermanyUnited Kingdom
In The Last Decade
Kiyoshi Sugihara
7 papers receiving 351 citations
Hit Papers
Peers
Comparison fields: 5 of 49
- Oncology 292
- Radiology, Nuclear Medicine and Imaging 167
- Pulmonary and Respiratory Medicine 113
- Molecular Biology 64
- Cancer Research 33
Countries citing papers authored by Kiyoshi Sugihara
This map shows the geographic impact of Kiyoshi Sugihara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kiyoshi Sugihara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kiyoshi Sugihara more than expected).
Fields of papers citing papers by Kiyoshi Sugihara
This network shows the impact of papers produced by Kiyoshi Sugihara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kiyoshi Sugihara. The network helps show where Kiyoshi Sugihara may publish in the future.
Co-authorship network of co-authors of Kiyoshi Sugihara
This figure shows the co-authorship network connecting the top 25 collaborators of Kiyoshi Sugihara. A scholar is included among the top collaborators of Kiyoshi Sugihara based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kiyoshi Sugihara. Kiyoshi Sugihara is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 24 | |
| 2 | 32 | |
| 3 | The Latest Research and Development into the Antibody–Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapybreakdown → | 275 |
| 4 | 2 | |
| 5 | 20 | |
| 6 | 7 | |
| 7 | In Vivo Pharmacodynamic Activity of Tomopenem (formerly CS-023) Against Pseudomonas aeruginosa and MRSA in Murine Thigh Infection Model | 1 |
About Kiyoshi Sugihara
Kiyoshi Sugihara is a scholar working on Molecular Medicine, Pharmacology and Oncology, having authored 7 papers that have together received 361 indexed citations. Recurring topics across this work include Antibiotics Pharmacokinetics and Efficacy (4 papers), Antibiotic Resistance in Bacteria (3 papers) and HER2/EGFR in Cancer Research (2 papers). The work is most often cited by research in Oncology (292 citations), Radiology, Nuclear Medicine and Imaging (167 citations) and Molecular Medicine (20 citations). Kiyoshi Sugihara has collaborated with scholars based in Japan, Germany and United Kingdom. Frequent co-authors include Toshinori Agatsuma, Takahiro Jikoh, Takashi Nakada, Yuki Abe, Teiji Wada, Tetsufumi Koga, Masayo Kakuta, Mikiko Suzuki, Tadaaki Nishikawa and Yusuke Ogitani. Their work appears in journals such as PLoS ONE, Clinical Cancer Research and Antimicrobial Agents and Chemotherapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.